Drug ID:Drug100
Drug Name:Ceftriaxone
CID:5479530
DrugBank ID:DB01212
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT03794765
Molecular Formula:C18H18N8O7S3
Molecular Weight:554.6 g/mol
Isomeric SMILES:CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
Synonyms:ceftriaxone; 73384-59-5; Biotrakson; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Ceftriaxonum [INN-Latin]; Ceftriaxona [INN-Spanish]; Cefatriaxone
Phase 0: 4
Phase 1: 13
Phase 2: 36
Phase 3: 51
Phase 4: 53
Description:A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem]

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt851 5479530 Ceftriaxone 2539 G6PD Homo sapiens (human) None
dt852 5479530 Ceftriaxone 1727 CYB5R3 Homo sapiens (human) None
dt853 5479530 Ceftriaxone 7124 TNF Rattus norvegicus (Norway rat) 25053526 Ropinirole promotes the reaction [ceftriaxone inhibits the reaction [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]|ceftriaxone inhibits the reaction [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in i
dt854 5479530 Ceftriaxone 59272 ACE2 Rattus norvegicus (Norway rat) 29745864 Ceftriaxone results in decreased expression of ACE2 mRNA
dt855 5479530 Ceftriaxone 60 ACTB Rattus norvegicus (Norway rat) 29745864 Ceftriaxone results in increased expression of ACTB mRNA
dt856 5479530 Ceftriaxone 213 ALB Homo sapiens (human) 16485100 Ceftriaxone binds to ALB protein
dt857 5479530 Ceftriaxone 23621 BACE1 Rattus norvegicus (Norway rat) 29745864 Ceftriaxone results in decreased expression of BACE1 mRNA
dt858 5479530 Ceftriaxone 847 CAT Mus musculus (house mouse) 19442074 Ceftriaxone results in decreased expression of CAT protein
dt859 5479530 Ceftriaxone 847 CAT Rattus norvegicus (Norway rat) 25053526 Ropinirole promotes the reaction [ceftriaxone inhibits the reaction [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]|ceftriaxone inhibits the reaction [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in dec

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03794765 Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis PHASE2 COMPLETED Post Graduate Institute of Medical Education and Research, Chandigarh Ulcerative Colitis|Inflammatory Bowel Diseases|Ac… DRUG: Ceftriaxone|DRUG: Metronidazole|OTHER: Plac… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Ceftriaxone causes dysbiosis and changes intestinal structure in adjuvant obesi…

PMID: 34757518
Year: 2022
Relationship Type: Treatment Score: 9.5

BACKGROUND: Obesity is still a worldwide public health problem, requiring the development of adjuvant therapies to combat it. In this context, modula…

View Details
Carbohydrate composition of rat intestine surface mucus layer after ceftriaxone…

PMID: 29235834
Year: 2016
Relationship Type: Treatment Score: 9.3

The epidemiological studies have shown that antibiotic treatment increases the susceptibility to inflammatory bowel disease development. The disturba…

View Details